Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Review outlines how SIRT3 protein regulates global metabolic disorders

A comprehensive review published in Engineering systematically outlines the regulatory capacity of silent information regulator 3 (SIRT3), a mitochondrial deacetylase termed the "head goose molecule", and its negentropic mechanism for intervening global metabolic disorders including type 2 diabetes, obesity, and steatotic liver disease.

21 Aug 2026

Autophagy modulation emerges as a strategy against cisplatin-resistant gastric cancer

Drug resistance remains one of the greatest obstacles to successful treatment of gastric cancer, limiting the long-term effectiveness of the widely used chemotherapy drug cisplatin.

6 Aug 2026

Early electroacupuncture intervention protects pancreatic function in prediabetes

Prediabetes refers to a metabolic state in which blood glucose is higher than normal but has not yet reached the diagnostic threshold for diabetes. It may involve impaired fasting glucose, impaired glucose tolerance, or elevated glycated hemoglobin A1c (HbA1c), and is closely associated with progressive β-cell dysfunction.

21 Jul 2026

Popular diabetes drugs do not alter the risk of developing a blinding eye condition

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of medication that mimics the GLP-1 hormone - to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.

17 Jul 2026

Semaglutide dose may matter more than weight loss for heart health

The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging existing treatment assumptions.

14 Jul 2026

Distinct gut microbiome signatures identify frailty in older women

Research reveals gut microbiome signatures linked to frailty in older women, highlighting microbial changes associated with mortality and physical decline.

13 Jul 2026

Nine gut bacteria linked to future type 2 diabetes risk

Research identifies specific gut microbes associated with future type 2 diabetes risk, emphasizing the impact of dietary fiber on microbiome health.

9 Jul 2026

GLP-1 medications may improve long-term health for people with peripheral artery disease

GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease), according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

1 Jul 2026

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

24 Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

18 Jun 2026

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

11 Jun 2026

Gut bacterial molecule reduces intestinal inflammation by slowing cell energy

Enterobactin, a molecule produced by gut bacteria, may hold a surprising key to reducing intestinal inflammation. Not by attacking the immune system directly, but by temporarily slowing down the cell's own energy production.

11 Jun 2026

Injectable semaglutide may improve fertility outcomes in PMOS

Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

9 Jun 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

Explainable AI could make breast cancer drug predictions safer and clearer

AI-driven genomic analysis could help researchers identify existing drugs that may be repurposed for subtype-specific breast cancer treatment. The review proposes an interpretability-driven framework that links multi-omics data, mechanistic validation, and clinical translation to make AI predictions more transparent and clinically useful.

22 May 2026

Global consortium renames polycystic ovary syndrome to reflect science

First, it was named after two men. Then, it was named for a false premise. Now, after more than a century, one of the most common hormone disorders affecting women worldwide has a name that reflects the science.

18 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

Four OICR-funded studies explore transformative approaches in cancer care

Four new research studies funded by the Ontario Institute for Cancer Research (OICR) will deliver cutting-edge innovations by maximizing the impact of existing research and making the most out of patient contributions.

13 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026